Publication:
Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry

No Thumbnail Available

Date

2022-06-03

Authors

Gimeno, Juan R.
Olivotto, Iacopo
Isabel Rodriguez, Ana
Ho, Carolyn Y.
Fernandez, Adrian
Quiroga, Alejandro
Angeles Espinosa, Mari
Gomez-Gonzalez, Cristina
Robledo, Maria
Tojal-Sierra, Lucas

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Wiley periodicals, inc
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Aims To describe the natural history of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy (HCM) compared with a control group and to identify predictors of adverse events.Methods and results Three hundred and five patients [age 56.6 +/- 16.9 years old, 191 (62.6%) male patients] with HCM and SARS-Cov-2 infection were enrolled. The control group consisted of 91 131 infected individuals. Endpoints were (i) SARS-CoV-2 related mortality and (ii) severe clinical course [death or intensive care unit (ICU) admission]. New onset of atrial fibrillation, ventricular arrhythmias, shock, stroke, and cardiac arrest were also recorded. Sixty-nine (22.9%) HCM patients were hospitalized for non-ICU level care, and 21 (7.0%) required ICU care. Seventeen (5.6%) died: eight (2.6%) of respiratory failure, four (1.3%) of heart failure, two (0.7%) suddenly, and three (1.0%) due to other SARS-CoV-2-related complications. Covariates associated with mortality in the multivariable were age {odds ratio (OR) per 10 year increase 2.25 [95% confidence interval (CI): 1.12-4.51], P = 0.02291, baseline New York Heart Association class [OR per one-unit increase 4.01 (95%CI: 1.75-9.20), P = 0.0011], presence of left ventricular outflow tract obstruction [OR 5.59 (95%CI: 1.16-26.92), P = 0.0317], and left ventricular systolic impairment [OR 7.72 (95%CI: 1.20-49.79), P = 0.0316]. Controlling for age and sex and comparing HCM patients with a community-based SARS-CoV-2 cohort, the presence of HCM was associated with a borderline significant increased risk of mortality OR 1.70 (95%CI: 0.98-2.91, P = 0.0600).Conclusions Over one-fourth of HCM patients infected with SARS-Cov-2 required hospitalization, including 6% in an ICU setting. Age and cardiac features related to HCM, including baseline functional class, left ventricular outflow tract obstruction, and systolic impairment, conveyed increased risk of mortality.

Description

MeSH Terms

DeCS Terms

CIE Terms

Keywords

Hypertrophic cardiomyopathy, COVID-19, SARS-CoV-2 infection, Heart failure, Registry, Prognosis, Classification, Cardiology, Statement, Covid-19, Disease

Citation